CureVac N.V. (CVAC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Alexander Zehnder M.B.A., M.D. | CEO, MD & Member of Management Board | 1.06M | -- | 1970 |
| Mr. Pierre Kemula B.Sc. | MD, CFO & Member of Management Board | 707.56k | -- | 1975 |
| Dr. Malte Greune Ph.D. | COO, Member of Management Board & MD | 649.76k | -- | 1965 |
| Dr. Myriam Mendila M.D. | Chief Scientific Officer, Head of R&D, MD & Member of the Management Board | 664.63k | -- | 1966 |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior VP & Area Head of Oncology | 307.33k | -- | 1973 |
| Dr. Sarah Fakih | Vice President Corporate Communications & Investor Relations | -- | -- | -- |
| Mr. Marco Rau L.L.M., Ph.D. | General Counsel | -- | -- | -- |
| Mr. Thorsten Schuller | Head of Corporate Communications | -- | -- | -- |
| Slavica Stevanovic-Heck | Head of Human Resources | -- | -- | -- |
| Dr. Patrick Baumhof | Senior Vice President of Technology | -- | -- | -- |
CureVac N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 999
Description
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Corporate Governance
Upcoming Events
August 15, 2024 at 10:59 AM UTC - August 19, 2024 at 12:00 PM UTC
CureVac N.V. Earnings Date